Clinical trials: Bone Marrow
Myelodysplastic Syndromes
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
This purpose of this study is to establish proof of concept of tebapivat in participants with LR-MDS in Phase 2a and to evaluate the effect of tebapivat on transfusion independence (TI) in participants with LR-MDS in phase 2b.
- Trial name
- NCT05490446
- Testing
- Tebapivat
- Where
- 45 sites in United States, Australia and 11 more
- Volunteers
- 87 people
- Sponsor
- Agios Pharmaceuticals, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome.
Master Protocol: The main goal of this master clinical trial study is to assesses the safety, tolerability, pharmacokinetic (PK), Pharmacodynamic (PD) in participants with relapsed or refractory acute myeloid leukemia (AML) or…
- Trial name
- NCT05457010
- Testing
- SPRX002, ARC-T Cells, Cyclophosphamide
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Kite, A Gilead Company
Polycythemia Vera
Study to Assess SLN124 in Patients With Polycythemia Vera
This is a Phase 1/2, multicenter study with an open-label dose escalation followed by a randomized placebo controlled and double-blind phase of SLN124 in adult patients with Polycythemia Vera (PV) to assess the safety…
- Trial name
- SLN (NCT05499013)
- Testing
- SLN124
- Where
- 28 sites in United States, Australia and 7 more
- Volunteers
- 69 people
- Sponsor
- Silence Therapeutics plc
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02
An open-label, phase I, multi-center study to determine in relapsed/refractory (r/r) acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) patients the recommended dose of CYAD-02 after a non-myeloablative…
- Trial name
- CYCLE-1 (NCT04167696)
- Testing
- CYAD-02, ENDOXAN, Fludara
- Where
- 5 sites in United States, Belgium
- Volunteers
- 27 people
- Sponsor
- Celyad Oncology SA
Paroxysmal Nocturnal Hemoglobinuria
Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria
This study was designed to provide continued access to BCX9930 for participants with Paroxysmal Nocturnal Hemoglobinuria (PNH) who had benefited from treatment with BCX9930 in another BioCryst-sponsored study for PNH who, in the…
- Trial name
- NCT05741346
- Testing
- BCX9930
- Where
- 11 sites in France, Hungary and 5 more
- Volunteers
- 28 people
- Sponsor
- BioCryst Pharmaceuticals
Myeloid Leukemia, Chronic
A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia
The objective is to evaluate the cytogenetic response to Dasatinib (BMS-354825) administered for 24 weeks in subjects with Imatinib resistant or intolerant chronic phase chronic myeloid leukemia (CML) once daily (QD) or twice…
- Trial name
- NCT00482703
- Testing
- Dasatinib
- Where
- 9 sites in Japan
- Volunteers
- 23 people
- Sponsor
- Bristol-Myers Squibb
Acute Myeloid Leukemia, Myelodysplastic Syndrome
A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
This is an open-label, dose escalation study to evaluate the safety, toxicity, and pharmacokinetics (PK) as well as preliminary efficacy of BTX-A51 capsules in participants with relapsed or refractory acute myeloid leukemia (AML)…
- Trial name
- NCT04243785
- Testing
- BTX-A51, Azacitidine
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- Edgewood Oncology Inc.
Essential Thrombocythemia (ET)
Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID®
This study is hypothesis-generating to explore the impact of JAK2 (V617F) mutation status on the treatment response to anagrelide hydrochloride
- Trial name
- EMIX (NCT01352585)
- Testing
- Anagrelide hydrochloride
- Where
- 10 sites in Italy
- Volunteers
- 47 people
- Sponsor
- Shire
Myelofibrosis, Polycythemia Vera
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
To determine the safety, tolerability and effectiveness of ruxolitinib (INCB018424), administered orally to patients with Primary Myelofibrosis (PMF), Post Polycythemia Vera Myelofibrosis (PPV-MF) and Essential Thrombocythemia…
- Conditions
- Myelofibrosis, Polycythemia Vera, Thrombocytosis
- Trial name
- NCT00509899
- Testing
- Ruxolitinib
- Where
- 2 sites in United States
- Volunteers
- 154 people
- Sponsor
- Incyte Corporation
Paroxysmal Nocturnal Hemoglobinuria
A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works
This study is researching an experimental treatment combination with two experimental drugs called pozelimab and cemdisiran. The study is focused on people with paroxysmal nocturnal hemoglobinuria (PNH).
- Trial name
- ACCESS-EXT (NCT05744921)
- Testing
- Pozelimab, Cemdisiran
- Where
- 48 sites in Brazil, Canada and 18 more
- Volunteers
- 202 people
- Sponsor
- Regeneron Pharmaceuticals
Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)
The purpose of this study is to evaluate the safety and efficacy of etavopivat (FT-4202) for the treatment of anemia in adult patients with very low risk, low risk, or intermediate risk MDS.
- Trial name
- NCT05568225
- Testing
- Etavopivat
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 17 people
- Sponsor
- Forma Therapeutics, Inc.
Essential Thrombocythemia (ET)
Pediatric Disease Registry in Essential Thrombocythaemia (ET)
The aim of this study is to evaluate the progression of ET in children (aged 6-17years inclusive) over a period of 5 years maximum.
- Trial name
- NCT01198717
- Where
- 32 sites in Czechia, France and 6 more
- Volunteers
- 60 people
- Sponsor
- Shire
Myelodysplastic Syndromes
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
This study will determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and recommended Phase 2 dose (RP2D) of SX-682 in the treatment of patients with Myelodysplastic Syndromes (MDS).
- Trial name
- NCT04245397
- Testing
- SX-682, Decitabine
- Where
- 7 sites in United States
- Volunteers
- 151 people
- Sponsor
- Syntrix Biosystems, Inc.
Chronic Myeloid Leukemia
Real-World Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia in Earlier Lines of Therapy
This was a retrospective, non-interventional, observational cohort study using Optum's de-identified Clinformatics® Data Mart Database.
- Trial name
- ABL-2022-03 (NCT06692803)
- Where
- United States
- Volunteers
- 2,043 people
- Sponsor
- Novartis Pharmaceuticals
Previously Treated PH + CML
Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors
The purpose of this study is to fulfill the post-authorization commitment made by Pfizer to the European Medicines Agency in providing additional safety and efficacy data in approximately 150 Philadelphia Chromosome Positive…
- Trial name
- NCT02228382
- Testing
- Bosutinib
- Where
- 48 sites in United States, Austria and 6 more
- Volunteers
- 163 people
- Sponsor
- Pfizer
Essential Thrombocythemia (ET), Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis
This study aims to assess the safety and efficacy of orally administered JBI-802 in subjects with Myeloproliferative Neoplasms (MPN) and Myelodysplastic/ Myeloproliferative Neoplasms (MDS/MPN) with Thrombocytosis.
- Conditions
- Essential Thrombocythemia (ET), Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Myeloproliferative Neoplasms (MPN)
- Trial name
- NCT07612280
- Testing
- JBI-802
- Where
- 7 sites in Australia
- Volunteers
- 30 people
- Sponsor
- Jubilant Therapeutics Inc.
Chronic Myeloid Leukemia
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
This is an open-label, continuous daily dosing, two-part safety and efficacy study of SKI-606 (bosutinib) in Philadelphia chromosome positive leukemias (Ph+).
- Trial name
- NCT00261846
- Testing
- Bosutinib
- Where
- 111 sites in United States, Argentina and 25 more
- Volunteers
- 571 people
- Sponsor
- Pfizer
Chronic Myelogenous Leukemia in Chronic Phase
Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)
This study will assess the safety and efficacy of imatinib in newly enrolled previously untreated patients with chronic phase CML.
- Trial name
- NCT00237120
- Testing
- Imatinib
- Volunteers
- 100 people
- Sponsor
- Novartis
Myeloproliferative Disorders, Thrombocythemia, Essential
A Study in Myeloproliferative Disorders
The purpose of this study is to find out the safe dose range of the study drug in patients with myeloproliferative disorders.
- Conditions
- Myeloproliferative Disorders, Thrombocythemia, Essential, Polycythemia Vera, Primary Myelofibrosis
- Trial name
- NCT01134120
- Testing
- LY2784544
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Eli Lilly and Company
Myelodysplastic Syndrome
Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome
To estimate the percent of patients with myelodysplastic syndromes (MDS) who experience erythroid response and the interval to response with daily treatment of 25 mg of CC-5013 .
- Trial name
- NCT00044382
- Testing
- CC-5013
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Celgene
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.